Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
A Phase 1/2a dose escalation and dose ranging study of FF-10101-01 in subjects with relapsed
or refractory acute myeloid leukemia to determine the safety, tolerability, PK and
preliminary efficacy. A total of 9 cohorts will be enrolled in Phase 1 to establish the
Maximum Tolerated Dose (MTD). Phase 2a will consist of up to 3 dose levels (high, medium, and
low) of which subjects with FLT3 mutations will randomly be assigned.